Kohei Shitara
设乐研也
MD, PhD
Chief, Department of Gastroenterology and Gastrointestinal Oncology消化内科及胃肠肿瘤学科主任
👥Biography 个人简介
Dr. Kohei Shitara is a world-leading gastric cancer specialist in Japan. He led the DESTINY-Gastric01 trial that established trastuzumab deruxtecan for HER2-positive gastric cancer, and has driven multiple global phase III trials redefining gastric cancer treatment across all lines.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Trastuzumab Deruxtecan (T-DXd)
Led DESTINY-Gastric01, the pivotal trial establishing T-DXd as a breakthrough second-line therapy for HER2-positive advanced gastric cancer, gaining global regulatory approval.
Nivolumab Third-Line Gastric Cancer
Led the ATTRACTION-2 trial demonstrating nivolumab monotherapy improved OS over placebo in heavily pretreated Asian patients, establishing immunotherapy in later-line gastric cancer.
Representative Works 代表性著作
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer (DESTINY-Gastric01)
New England Journal of Medicine (2020)
Landmark phase II trial showing T-DXd achieved 43% ORR vs 13% for chemotherapy, leading to FDA breakthrough designation and approval in HER2+ gastric cancer.
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3)
The Lancet Oncology (2019)
Established nivolumab as second-line standard for esophageal SCC, improving OS regardless of PD-L1 expression.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 设乐研也 的研究动态
Follow Kohei Shitara's research updates
留下邮箱，当我们发布与 Kohei Shitara（National Cancer Center Hospital East, Japan）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment